Physician profile
Naveen K Mittal
NPI 1114989977
$182,281.07
in general payments reported to CMS, 2019-2025
22 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $3,977 · 2021: $108 · 2022: $36K · 2023: $40K · 2024: $17K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $46K · Travel and Lodging: $8,885 · Food and Beverage: $5,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,680.20 |
| Consulting Fee | $46,328.70 |
| Travel and Lodging | $8,884.92 |
| Food and Beverage | $5,152.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $57,647.62 | 2023-2025 | Bylvay, Iqirvo |
| Fresenius Kabi USA, LLC | $50,136.06 | 2019-2025 | Smoflipid |
| Albireo Pharma, INC. | $30,216.56 | 2022-2023 | Bylvay |
| Mirum Pharmaceuticals, INC. | $18,702.28 | 2022-2025 | Livmarli |
| Alexion Pharmaceuticals, INC. | $13,946.31 | 2019-2023 | |
| Travere Therapeutics, INC. | $9,884.98 | 2019-2022 | |
| Abbvie INC. | $393.44 | 2019-2023 | |
| Novo Nordisk INC | $240.32 | 2019-2023 | Wegovy |
| Medtronic, INC. | $224.68 | 2023-2025 | Endoflip |
| Takeda Pharmaceuticals U.S.A., INC. | $164.52 | 2022-2025 | Gattex |
| Intercept Pharmaceuticals, INC. | $123.63 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $108.77 | 2019 | |
| Pfizer INC. | $91.82 | 2019 | |
| Alcresta Therapeutics, INC. | $90.51 | 2023-2025 | Relizorb |
| Blueprint Medicines Corporation | $86.53 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $71.28 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $50.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $41.80 | 2025 | |
| Nestle Healthcare Nutrition INC. | $30.75 | 2021 | |
| Taiho Oncology, INC. | $28.24 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.